HUTCHMED China Ltd

AstraZeneca has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS, or savolitinib, plus TAGRISSO, or osimertinib, for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have MET overexpression or amplification and who progressed on or after an EGFR tyrosine kinase inhibitor therapy, HUTCHMED announced. The filing is supported by the global SAFFRON Phase III trial, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free survival and overall survival in this setting, versus doublet platinum-based chemotherapy in patients who progressed on TAGRISSO. SAFFRON enrolled 338 patients across 230 centers in 29 countries and builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials, with results to be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology Congress 2026. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca; the combination is already approved in China based on SACHI and received a temporary authorization in Switzerland based on SAVANNAH. Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said the filing is an important step toward potentially bringing the biomarker-directed, chemotherapy-free oral combination to patients in the US.

Chinese biopharma shares rallied on Monday after a report that the U.S. Treasury Department is drafting rules that would likely allow American pharmaceutical companies to invest in promising new drugs developed by Chinese firms, excluding those related to pathogens or biotechnology that could be weaponized. Innovent Biologics rose 7% and Akeso gained 8%, while HUTCHMED advanced 3% and Sino Biopharmaceutical added 8%, and the Hang Seng Biotech Index climbed more than 5%. The report follows Friday's news of the pending Treasury rules and comes as Chinese President Xi Jinping is set to meet with his American counterpart this week, at a time when other U.S. industries face a tighter regulatory environment for business dealings in China under new national security legislation. Almost half of U.S. deals to license drugs from overseas in 2025 were with Chinese companies, and China signed licensing deals worth a total $110B in the first half of 2026.

AstraZeneca has pledged to invest $15bn in China, deepening Western pharmaceutical ties with a country that has become a bona fide drug superpower even as Washington moves to sever them. The company's chief executive, Sir Pascal Soriot, announced the investment during Sir Keir Starmer's Beijing visit, building on existing manufacturing and research sites in Beijing, Shanghai, Wuxi, Taizhou and Qingdao; China is now AstraZeneca's second-largest market, accounting for roughly 12pc of global turnover, with around 17,000 employees and four advanced manufacturing sites. GSK has struck a series of partnerships with Chinese labs, including a $1.3bn pact with Hutchmed for the bulk of licensing rights to what it called first-in-class cancer treatments, and an alliance with Hengrui Pharma worth up to $12bn. Industry-wide licensing deals totalled $138bn last year, a nearly tenfold jump since 2021, according to PharmCube. The US Biosecure Act, signed into law in December, bars companies reliant on federal contracts from working with Chinese biotech firms tied to the military, and the proposed Biotech Investment National Security Act would subject licensing deals involving Chinese companies to national security reviews. China had 1,255 drugs at the research stage by 2024, a nearly eight-fold jump in less than a decade, against 1,441 in America and 400 in Europe.

AstraZeneca's late-stage trial found that combining Tagrisso with Orpathys significantly extended progression-free survival compared with Tagrisso alone in previously untreated patients with EGFR-mutated advanced non-small cell lung cancer whose tumors expressed moderate to high levels of the MET protein. Lead principal investigator Yi-Long Wu said the observed clinical benefit could reshape initial treatment for this distinct patient population. AstraZeneca also reported encouraging overall-survival benefits as a secondary objective, though the company did not establish that the result was statistically significant. The combination's safety profile was consistent with the known profiles of Tagrisso and Orpathys, with no new safety findings, but detailed adverse-event results have not yet been presented. The results could support AstraZeneca's target of $80 billion in total annual sales by 2030, with cancer medicines contributing nearly half of company sales and Tagrisso among its leading products; Orpathys is being developed with Hutchmed. A successful late-stage study does not by itself establish regulatory approval or commercial adoption, and much depends on the companies' application plans, regulatory timelines, and expected sales.

HUTCHMED has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, in a deal worth up to approximately $1.3 billion. The agreement includes a $110 million upfront payment and potential tiered royalties, with HUTCHMED leading global Phase I development before GSK assumes responsibility outside China. HMPL-A830 is designed to target EGFR-overexpressing tumor cells and deliver a KRAS payload, potentially addressing resistance to standalone KRAS inhibitors in colorectal, pancreatic, and lung cancers. HUTCHMED also granted GSK a right of first negotiation on another early-stage candidate from its ATTC platform. The company expects to present detailed data from two positive Phase III trials with AstraZeneca at a future conference, and anticipates milestone and royalty income from commercialized indications, including tiered royalties of 9% to 13% on global sales for the SAFFRON trial and 30% royalties from AstraZeneca for specified indications in China.

AstraZeneca announced positive results from the phase III SANOVO study, showing that Tagrisso plus Orpathys significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced or metastatic non-small cell lung cancer and MET overexpression. The study, conducted with partner HUTCHMED, also showed encouraging overall survival improvements, though follow-up continues. The combination is already approved in China for later-line treatment, and these results could support its use in the first-line setting. Year to date, AstraZeneca's shares have fallen 11.7%, compared with the industry's 8.7% growth.

HUTCHMED announced positive high-level results from the SANOVO China Phase III trial, showing that ORPATHYS plus TAGRISSO significantly improved progression-free survival versus TAGRISSO alone in treatment-naïve patients with MET-overexpressing EGFR-mutated non-small cell lung cancer. The combination also demonstrated encouraging overall survival benefit in both high MET and intention-to-treat populations, with the trial continuing follow-up. These findings extend the clinical value of the all-oral combination into the first-line setting, building on the global SAFFRON and China SACHI trials. The safety profile was consistent with known profiles of each medicine, and data will be presented at a forthcoming medical meeting. HUTCHMED plans to share the data with regulatory authorities to bring this combination to first-line treatment in China.

HUTCHMED and AstraZeneca announced positive high-level results from the global Phase III SAFFRON trial showing that ORPATHYS plus TAGRISSO significantly improved progression-free survival and overall survival versus platinum-based chemotherapy in patients with EGFR-mutated non-small cell lung cancer with high MET overexpression or amplification who had progressed on TAGRISSO. The trial enrolled 338 patients across 230 centers in 29 countries, and the safety profile was consistent with the known profiles of each medicine with no new safety findings. The companies plan to present the data at a forthcoming medical meeting and share it with global regulatory authorities. The combination is already approved in China based on the SACHI Phase III trial, and this is the first global Phase III trial to show significant progression-free and overall survival benefits in this setting.

HUTCHMED reported first-half 2026 oncology revenue of $162 million, a 23% increase year over year, and maintained its full-year oncology revenue guidance of $330 million to $415 million. The company posted net income of $16 million and ended the period with $1.4 billion in cash. China sales of ELUNATE and SULANDA each grew more than 40%, while global in-market sales of FRUZAQLA rose 40%, with sales outside the U.S. up 70%. Management noted that FRUZAQLA's international growth runway remains significant as reimbursement coverage is about 50%. The company also highlighted upcoming savolitinib data readouts, positive Phase III results for sovleplenib in warm autoimmune hemolytic anemia, and the initiation of a Phase III trial for HMPL-760 in diffuse large B-cell lymphoma, and said it is in active discussions with multinational companies about potential collaborations for its ATTC programs.

HUTCHMED announced that China's NMPA has granted conditional approval for ORPATHYS® (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. The approval is supported by a pivotal Phase II study where the IRC-assessed objective response rate was 32.3%, with a disease control rate of 63.1% and median duration of response of 9.7 months. MET amplification accounts for approximately 4-6% of gastric cancer patients, with an estimated annual incidence of about 18,000 in China. This marks the third approved indication for ORPATHYS® in China, which is jointly developed with AstraZeneca and marketed by AstraZeneca.

HUTCHMED announced that the pivotal Phase 2 registrational study of fanregratinib met its primary endpoint in intrahepatic cholangiocarcinoma, a type of bile duct cancer. The trial reported an objective response rate of 42.5% as assessed by an independent review committee. Key secondary endpoints included a median response time of 1.4 months, median duration of response of 6.9 months, disease control rate of 83.9%, median progression-free survival of 6.9 months, and median overall survival of 16.6 months. The company's New Drug Application for fanregratinib in previously treated advanced FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma was accepted for review and granted priority review by the Chinese National Medical Products Administration in December 2025. Fanregratinib is an investigational selective inhibitor of fibroblast growth factor receptors 1, 2, and 3.